Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerBilling CodesProprietary Laboratory AnalysesCPT cpt-0619u-trud-mds-copd-dna-methylation-test
    Ask Trek AI about this page

    CPT 0619U: TruD MDS COPD DNA Methylation Blood Test

    CPT code 0619U is a Proprietary Laboratory Analyses (PLA) code for the TruD MDS COPD test from TruDiagnostic™ Inc., a whole-blood DNA methylation assay that analyzes methylation at more than 18,000 sites and uses an algorithm to report a positive or negative risk for pulmonary chronic obstructive pulmonary disease (COPD); this service is a molecular diagnostic laboratory test performed on a collected whole blood specimen, typically resulting from outpatient phlebotomy and processed in a clinical diagnostic laboratory.

    For related coverage guidance, see recent payer policy updates: Minimal Residual Disease (MRD) Testing for Cancer, Biomarker Testing Mandate, Prenatal (Fetal) Diagnostic Testing.

    Customize your policy alerts

    Sign up for cpt 0619U policy alerts

    Get alerted when payer policies referencing 0619U are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 7

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical adult patient with a history of tobacco use, chronic respiratory symptoms, or an abnormal spirometry result presents to a primary care clinician or pulmonologist for risk stratification for chronic obstructive pulmonary disease (COPD). The clinician orders the proprietary TruD MDS COPD test (0619U) performed by TruDiagnostic™ Inc., which requires a whole blood sample collected in a standard phlebotomy setting. The blood specimen is sent to the manufacturer’s laboratory; results are returned as a binary risk output (positive or negative) based on methylation profiling at >18,000 CpG sites and a proprietary algorithm.

    Clinical workflow:

    • The clinician documents indications such as unexplained chronic cough, dyspnea, history of smoking, or abnormal pulmonary function testing and places the order for the TruD MDS COPD test (0619U).

    • A phlebotomy technician collects a whole blood specimen at an outpatient clinic, hospital outpatient lab, or ambulatory phlebotomy site; specimen handling and shipping follow the laboratory’s required protocol.

    • The specimen is transported to the manufacturer’s reference laboratory for DNA extraction, methylation analysis, and algorithmic interpretation.

    • The laboratory issues a report with a positive or negative COPD risk result to the ordering clinician. The clinician integrates the test result with clinical evaluation, smoking history, spirometry, imaging, and other diagnostic data to inform risk assessment and management planning.

    Typical site of service: outpatient clinic, ambulatory phlebotomy center, hospital outpatient laboratory, or reference lab processing location.

    Service type: Proprietary Laboratory Analysis (PLA) — high-complexity molecular diagnostic testing performed by a single laboratory/manufacturer.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    0619UTruD MDS COPD — DNA methylation analysis of >18,000 sites, whole blood; proprietary test providing positive/negative COPD riskPrimary PLA code for the proprietary methylation-based COPD risk assay performed by TruDiagnostic™ Inc.; billed when the manufacturer’s test is ordered and processed.
    36415Collection of venous blood by venipuncturePerformed at the ordering site to obtain the whole blood specimen required for 0619U.
    99000Handling and/or conveyance of specimen to reference laboratory (if payer allows)May be used per payer or facility policy to report special specimen handling/shipping when separate reimbursement is permitted.
    G0499This code is not applicable to PLA testing and is listed here only if required by specific payers for molecular test reporting

    Related Modifiers

    6 rows

    ModifierDescriptionWhen to Use
    26Modifier 26 (Professional Component) identifies and bills only the professional portion of a split service — the physician’s interpretation, report, and medical judgment — when the technical…- Use CPT Modifier -26 when you are billing only the professional component (PC) of a split‑bill eligible service—i.e., you performed the physician interpretation, medical judgment and prepared a…
    90Modifier ‑90 (Reference/Outside Laboratory) indicates that a laboratory test was performed by an entity other than the treating or reporting provider. The American Medical Association defines…- Use CPT modifier -90 when a laboratory test is performed by an outside/reference laboratory (an entity other than the treating or reporting physician or qualified professional) and the claim needs…
    91Modifier 91 — “Repeat Clinical Diagnostic Laboratory Test” — is appended when the exact same CPT laboratory test is performed more than once for the same patient on the same day because serial,…- Use modifier 91 when the exact same CPT laboratory test is performed more than once on the same patient on the same date because serial or repeated testing is medically necessary to monitor…
    59Modifier 59 indicates a distinct procedural service when two procedures that are not normally billed together are clinically and procedurally separate. The CPT definition (as reiterated by CMS)…- Use modifier -59 to report a distinct procedural service when documentation supports that the procedure reported is not normally billed together with another service on the same day because of a…
    24Modifier 24 denotes an unrelated evaluation and management (E/M) service performed by the same physician or qualified healthcare professional during a postoperative global period. Per CPT guidance,…- Use modifier 24 when you report an evaluation and management (E/M) service performed by the same physician or same-specialty group during a procedure’s postoperative global period that is unrelated…
    25CPT modifier 25 indicates that on the same day as another procedure or service, the same physician or other qualified health care professional provided a significant, separately identifiable…- When to apply: Use modifier 25 only on an E/M code to indicate the same provider delivered a significant, separately identifiable E/M service on the same day as another procedure or service — i.e.,…

    Related Provider Taxonomies

    8 rows

    Taxonomy Code
    2084P0800X
    207Q00000X
    208000000X
    363A00000X
    2085N0700X
    163WF0300X
    207K00000X
    364SI0800X

    Related ICD-10-CM Codes

    29 rows

    ICD-10-CM CodeDescription
    E11.9Type 2 diabetes mellitus without complications
    E66.9Obesity, unspecified
    E78.5Hyperlipidemia, unspecified
    F17.200Nicotine dependence, unspecified, uncomplicated
    F17.210Nicotine dependence, cigarettes, uncomplicated
    I10Essential (primary) hypertension
    J42Unspecified chronic bronchitis
    J43.0Unilateral pulmonary emphysema [MacLeod's syndrome]
    J43.1Panlobular emphysema
    J43.8Other emphysema

    Showing 1–10 of 29

    Related Payer Policy Updates

    Specialty: Genetic & Molecular Testing1 / 3

    10 rows

    PolicyPayerEffective Date
    Minimal Residual Disease (MRD) Testing for Cancerregence2027-01-01
    Biomarker Testing MandateBlue Cross Blue Shield - Rhode Island2027-01-01
    Prenatal (Fetal) Diagnostic TestingBlue Cross Blue Shield - Rhode Island2027-01-01
    Oral Cancer Screening and TestingOscar Health2027-01-01
    RTM Testing for Alpha-1 Antitrypsin DeficiencyOscar Health2027-01-01
    Cytochrome P450 Genotype-Guided Treatment Strategy Corporate Medical Policybcbsvermont2027-01-01
    Cytochrome P450 Genotypingblue cross blue shield - tennessee2026-12-31
    Polygenic Risk ScoreBlue Cross Blue Shield - Rhode Island2026-12-01
    Gene Expression Profiling for Cutaneous MelanomaBlue Cross Blue Shield - Rhode Island2026-12-01
    Genetic Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancerblue_shield_of_california2026-11-01

    Related Codes

    CPT-0001U-PRECISETYPE-HEA-MULTIPLEX-RBC-ANTIGEN-GENOTYPING

    CPT 0001U: PreciseType HEA Erythrocyte Antigen Genotyping

    CPT-0002U-POLYPDX-URINE-METABOLOMIC-ASSAY-ADENOMATOUS-POLYP-RISK

    CPT 0002U: PolypDX™ Urine Metabolomic Risk Assay

    CPT-0003U-OVAR-A-NEXT-GENERATION-OVARIAN-CANCER-RISK-ASSAY

    CPT 0003U: Overa (MIA2G) Ovarian Cancer Risk Assay

    CPT-0005U-PROSTATE-EXOSOMEDX-INTELLISCORE-GENE-EXPRESSION-URINE-TEST

    CPT 0005U: ExosomeDx Prostate (IntelliScore) urine gene expression test

    CPT-0007U-TOXPROTECT-URINE-DRUG-SCREEN-WITH-DNA-AUTHENTICATION

    CPT 0007U: ToxProtect Urine Drug Screen With DNA Authentication

    CPT-0008U-H-PYLORI-ANTIBIOTIC-RESISTANCE-SEQUENCING-PANEL

    CPT 0008U: H. pylori Antibiotic Resistance Gene Panel

    CPT-0009U-DEPARRAY-HER2-FISH-TUMOR-CELL-ISOLATION

    CPT 0009U: DEPArray HER2 Tumor‑Cell Isolation with FISH Analysis

    CPT-0010U-BACTERIAL-TYPING-WHOLE-GENOME-SEQUENCING-MAYO-CLINIC

    CPT 0010U: Bacterial Typing by Whole Genome Sequencing, Mayo Clinic

    CPT-0011U-CORDANT-CORE-ALGORITHMIC-ORAL-FLUID-DRUG-TEST

    CPT 0011U: Oral Fluid Drug Test with Algorithmic Steady‑State Comparison

    CPT-0016U-BCR-ABL1-MAJOR-MINOR-FUSION-TRANSCRIPT-TESTING

    CPT 0016U: BCR–ABL1 Major and Minor Breakpoint Fusion Transcripts

    Showing 1–10 of 536

    • More pages

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

    Use only if a payer explicitly requires an alternate lab reporting code in conjunction with a PLA test (payer-specific situations).
    CPT not providedData not available in the input.Additional local or payer-specific laboratory billing codes may apply for courier services, accessioning, or facility charges; use institutional billing guidance.